The Asia-Pacific Infectious Disease Therapeutics Market was worth 16.82 USD Billion in 2019 and estimated to reach USD 26.2 Billion by the end of 2024 with a growing potential of 9.27%. Asia-Pacific is expected to account the second largest share in the market due to increasing pool of patients, and government funding.
Various microorganisms like bacteria, fungi, viruses and parasites and others causes infectious diseases such as HIV, malaria, tuberculosis, influenza. Various infectious diseases are mostly caused by poor sanitation and inadequate personal hygiene. These diseases are transmitted either through direct or indirect contact. Anti-infective drugs are used to inhibit or destroy the growth of disease causing agents. Antibacterial, antifungal, antiparasitic, antiviral drugs are some of the anti- infective drugs used for the treatment of these diseases.
Asia-Pacific market is mainly driven by growing incidence of infectious diseases, rising health care expenditure and growing geriatric population, growing healthcare awareness, increasing government funding’s in developing countries. Generic erosion, Patent expiration of infectious disease drugs are the factors that are hampering the growth of the market.
The Asia-Pacific Infectious disease therapeutics market is categorized based on Mode of treatment into Drugs and Vaccines. The drugs are further segmented into oral administration, topical, injections and others. Based on target organism the market is categorized into antibacterial, antifungal, antiviral, antiparasitic and others. Based on infection type the market is categorized into Bacterial, viral, fungal, parasite and others. Based on distribution channels the market is categorized into hospitals, clinics and others. Based on Geography, the Asia-Pacific Infectious disease therapeutics market is analyzed under various regions namely China, India, Japan and Australia.
some of the major companies operating in Asia-Pacific Infectious disease Therapeutics Market F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, , AstraZeneca, Auritec Pharmaceuticals, Bayer, Astellas Pharma, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida, Bristol-Myers Squibb, Sanofi.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Mode of Treatment
5.1.1 Introduction
5.1.2 Drugs
5.1.2.1 Oral Administration
5.1.2.2 Topical
5.1.2.3 Injections
5.1.2.4 Others
5.1.3 Vaccines
5.1.4 Y-o-Y Growth Analysis, By Mode of treatment
5.1.5 Market Attractiveness Analysis, By Mode of treatment
5.1.6 Market Share Analysis, By Mode of treatment
5.2 Target Organism
5.2.1 Introduction
5.2.2 Antibacterial
5.2.3 Antifungal
5.2.4 Antiviral
5.2.5 Antiparasite
5.2.6 others
5.2.7 Y-o-Y Growth Analysis, By Target Organism
5.2.8 Market Attractiveness Analysis, By Target Organism
5.2.9 Market Share Analysis, By Target Organism
5.3 Infection type
5.3.1 Introduction
5.3.2 Bacterial
5.3.3 Viral
5.3.4 Fungal
5.3.5 parasitic
5.3.6 others
5.3.7 Y-o-Y Growth Analysis, By Infection type
5.3.8 Market Attractiveness Analysis, By Infection type
5.3.9 Market Share Analysis, By Infection Type
5.4 Distribution Channels
5.4.1 Hospitals
5.4.2 Clinics
5.4.3 Others
5.4.4 Y-o-Y Growth Analysis, By Distribution Channels
5.4.5 Market Attractiveness Analysis, By Distribution Channels
5.4.6 Market Share Analysis, By Distribution Channels
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Mode of Treatment
6.1.3.3 By Target organism
6.1.3.4 By Infection Type
6.1.3.5 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Mode of Treatment
6.1.4.3 By Target organism
6.1.4.4 By Infection Type
6.1.4.5 By Distribution Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Mode of Treatment
6.1.5.3 By Target organism
6.1.5.4 By Infection Type
6.1.5.5 By Distribution Channels
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 F. Hoffmann-La Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Gilead Sciences
8.3 GlaxoSmithKline
8.4 Johnson & Johnson
8.5 Merck & Co
8.6 Pfizer
8.7 Achillion Pharmaceuticals
8.8 Novartis
8.9 Abbvie
8.10 Astellas Pharma
8.11 AstraZeneca
8.12 Auritec Pharmaceuticals
8.13 Bayer
8.14 Bristol-Myers Squibb
8.15 Chimerix Pharmaceuticals
8.16 Cubist
8.17 Eli Lilly
8.18 Isis Pharmaceuticals
8.19 pSivida
8.20 Sanofi
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
